What does Amycretin do? Benefits and evidence
An experimental fullness-hormone drug studied as daily tablets and weekly injections.
Also called: Zenagamtide, NNC0487-0111, NN9487, NN 9487.
Amylin / GLP-1 co-agonists · Unimolecular GLP-1 and amylin receptor agonist; also activates calcitonin receptors.
Amycretin, now called zenagamtide, combines GLP-1 and amylin signals in one molecule. Trials show weight loss and lower blood sugar, with phase 3 studies underway. It has no approved product or dose label. Nausea, vomiting and bowel problems are common, and many people stopped higher trial doses. Long-term benefits and risks remain unknown.
- In early trials, both weekly shots and daily tablets reduced weight, though the studies were small and short. (Studied in a trial)
- In type 2 diabetes trials, all three tablet doses and the weekly shots lowered blood sugar (HbA1c). (Studied in a trial)
- One blinded trial volunteer reported feeling full sooner, but did not know if they got the drug or a placebo. (Reported by users)
Uses in the sources
- Studied for weight loss in adults with overweight or obesity. Early injection trials lasted 20–36 weeks; phase 3 results are not yet available. (Studied in a trial) (source)
- Studied for blood sugar control in type 2 diabetes, added to metformin with or without an SGLT2 inhibitor. (Studied in a trial) (source)
- Trials are testing knee pain, sleep apnea, heart failure and cardiovascular outcomes. Benefit for these conditions has not been established. (Studied in a trial) (source)
Sources
- 21 CFR 216.23 — Bulk drug substances that can be used to compound drug products in accordance with section 503A of the Federal Food, Drug, and Cosmetic Act., Office of the Federal Register · eCFR · 2026
- 503B Bulk Drug Substances List, FDA · FDA · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2026
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act, FDA · FDA · 2026
- FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss, FDA · FDA · 2026
- The 2026 Prohibited List, World Anti-Doping Agency · WADA · 2026
- Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026, Australian Government · Australian Government · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2025
- Wegovy PI, Novo Nordisk
- Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists and Co-agonists for Weight Loss Among Adults Without Diabetes : An Updated Systematic Review., Moiz A et al. · Annals of internal medicine · 2026
- Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial., Mora P et al. · Lancet (London, England) · 2026
- Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial., Mora P et al. · Lancet (London, England) · 2026
- Novel Amylin-Based Therapies for Weight Management in Adults With Overweight or Obesity Without Diabetes: A Network Meta-Analysis., Kamrul-Hasan ABM et al. · Endocrinology, diabetes & metabolism · 2026
- Renal Impairment Does Not Affect Pharmacokinetics, Safety or Tolerability of Zenagamtide., Oldenburg LIK et al. · Diabetes, obesity & metabolism · 2026
- Supplementary appendix, Mora P et al. · The Lancet · 2026
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.